Anebulo Pharmaceuticals, Inc. (OTCPK: ANEB)
Health Care · Pharmaceuticals · US
$0.32
+5.12% today · -87.6% 1Y
Anebulo Pharmaceuticals, Inc. (OTCPK: ANEB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $13.05M and employs 3 people.
Over the last twelve months the share price has lost 87.6%, trading between 0.00 and 2.90.
Tweenvest scores Anebulo Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ANEB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- -1.82
- 52-week high
- $2.90
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 40.78M
- Employees
- 3
- Next earnings
- —
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
- ISIN
- US0345691036
- Founded
- 2020
- Listed since
- May 7, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.58 | +0.05% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.39 | -0.60% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.23 | +0.38% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.